These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26990539)

  • 21. Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
    Duan JJ; Jiang B; Lu Z; Stachura S; Weigelt CA; Sack JS; Khan J; Ruzanov M; Wu DR; Yarde M; Shen DR; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127441. PubMed ID: 32736080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
    Li X; Yeh V; Molteni V
    Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of new liver X receptor agonists by pharmacophore modeling and shape-based virtual screening.
    Temml V; Voss CV; Dirsch VM; Schuster D
    J Chem Inf Model; 2014 Feb; 54(2):367-71. PubMed ID: 24502802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-dimensional pharmacophore modeling of liver-X receptor agonists.
    Zhao W; Gu Q; Wang L; Ge H; Li J; Xu J
    J Chem Inf Model; 2011 Sep; 51(9):2147-55. PubMed ID: 21434646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic opportunities for liver X receptor modulators.
    Collins JL
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):692-702. PubMed ID: 15503871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design technology contour and its application to the design of renin inhibitors.
    Ishchenko A; Liu Z; Lindblom P; Wu G; Jim KC; Gregg RD; Claremon DA; Singh SB
    J Chem Inf Model; 2012 Aug; 52(8):2089-97. PubMed ID: 22805048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Spiro[pyrrolidine-3,3'-oxindole] LXRβ Agonists for the Treatment of Osteoporosis.
    Chen H; Hua P; Huang D; Zhang Y; Zhou H; Xu J; Gu Q
    J Med Chem; 2023 Jan; 66(1):752-765. PubMed ID: 36539349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.
    Washburn DG; Hoang TH; Campobasso N; Smallwood A; Parks DJ; Webb CL; Frank KA; Nord M; Duraiswami C; Evans C; Jaye M; Thompson SK
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1097-100. PubMed ID: 19167885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity.
    Chao EY; Caravella JA; Watson MA; Campobasso N; Ghisletti S; Billin AN; Galardi C; Wang P; Laffitte BA; Iannone MA; Goodwin BJ; Nichols JA; Parks DJ; Stewart E; Wiethe RW; Williams SP; Smallwood A; Pearce KH; Glass CK; Willson TM; Zuercher WJ; Collins JL
    J Med Chem; 2008 Sep; 51(18):5758-65. PubMed ID: 18800767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of 5α, 6α-epoxycholesterol as a novel modulator of liver X receptor activity.
    Berrodin TJ; Shen Q; Quinet EM; Yudt MR; Freedman LP; Nagpal S
    Mol Pharmacol; 2010 Dec; 78(6):1046-58. PubMed ID: 20837678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of liver X receptor attenuates endothelin-1 expression in vascular endothelial cells.
    Gao M; Zeng Y; Guan Y; Hu Z; Zhong D; Shen X; Zhang L; Xu Z; Gong W; Zhang Y; Zhang M; Zheng Y; He F
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2299-307. PubMed ID: 23018104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury.
    Lei P; Baysa A; Nebb HI; Valen G; Skomedal T; Osnes JB; Yang Z; Haugen F
    Basic Res Cardiol; 2013 Jan; 108(1):323. PubMed ID: 23266787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.
    Bernotas RC; Kaufman DH; Singhaus RR; Ullrich J; Unwalla R; Quinet E; Nambi P; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem; 2009 Dec; 17(23):8086-92. PubMed ID: 19853462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver X Receptor activation delays chondrocyte hypertrophy during endochondral bone growth.
    Sun MM; Beier F
    Osteoarthritis Cartilage; 2014 Jul; 22(7):996-1006. PubMed ID: 24852699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.
    Motoshima K; Noguchi-Yachide T; Sugita K; Hashimoto Y; Ishikawa M
    Bioorg Med Chem; 2009 Jul; 17(14):5001-14. PubMed ID: 19539483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
    Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton.
    Aoyama A; Endo-Umeda K; Kishida K; Ohgane K; Noguchi-Yachide T; Aoyama H; Ishikawa M; Miyachi H; Makishima M; Hashimoto Y
    J Med Chem; 2012 Sep; 55(17):7360-77. PubMed ID: 22873709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a selective agonist for liver X receptor α (LXRα) via screening of a synthetic compound library.
    Li N; Xu Y; Feng T; Liu C; Li Y; Wang X; Si S
    J Biomol Screen; 2014 Apr; 19(4):566-74. PubMed ID: 24334278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Aryl-N-acyl indole derivatives as liver X receptor (LXR) agonists.
    Kher S; Lake K; Sircar I; Pannala M; Bakir F; Zapf J; Xu K; Zhang SH; Liu J; Morera L; Sakurai N; Jack R; Cheng JF
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4442-6. PubMed ID: 17587573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages.
    Marino JP; Kallander LS; Ma C; Oh HJ; Lee D; Gaitanopoulos DE; Krawiec JA; Parks DJ; Webb CL; Ziegler K; Jaye M; Thompson SK
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5617-21. PubMed ID: 19717304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.